Dosimetric impact of post-operative seroma reduction during radiotherapy after breast-conserving surgery
Tanja Alderliesten, Suzanne Den Hollander, Tzu-I Jonathan Yang, Paula H.M. Elkhuizen, Anke M. Van Mourik, Coen Hurkmans, Peter Remeijer, Corine Van Vliet-Vroegindeweij

To cite this version:

HAL Id: hal-00796222
https://hal.archives-ouvertes.fr/hal-00796222
Submitted on 2 Mar 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Dosimetric impact of post-operative seroma reduction during radiotherapy after breast-conserving surgery

Tanja Alderliesten, PhD\textsuperscript{1}, Suzanne den Hollander, RT(T)\textsuperscript{1}, Tzu-I Jonathan Yang, BSRT(T)\textsuperscript{1,2}, Paula H M Elkhuisen, MD, PhD\textsuperscript{1}, Anke M van Mourik, PhD\textsuperscript{1}, Coen Hurkmans, PhD\textsuperscript{1}, Peter Remeijer, PhD\textsuperscript{1}, Corine van Vliet-Vroegindeweij, PhD\textsuperscript{1}

\textsuperscript{1} Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
\textsuperscript{2} Yale University School of Medicine, New Haven, CT, U.S.A.
\textsuperscript{3} Department of Radiation Therapy, Catharina Hospital, Eindhoven, The Netherlands

Corresponding Author: Corine van Vliet-Vroegindeweij, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands, Phone: +31 20 512 2243, Fax: +31 20 669 1101, Email: c.v.vliet@nki.nl

Key words: Breast cancer, Adaptive image guided radiotherapy, Boost volume, Post-operative seroma

ABSTRACT

\textit{Purpose:} Three boost radiotherapy (RT) techniques were compared to evaluate the dosimetric effect of seroma reduction during RT after breast-conserving surgery (BCS).

\textit{Materials and methods:} Twenty-one patients who developed seroma after BCS were included. Each patient underwent three CT scans: one week before RT (CT\textsubscript{1}), in the third (CT\textsubscript{3}) and fifth (CT\textsubscript{5}) week of RT. For each patient, three plans were generated. 1) SEQ: whole breast irradiation planned on CT\textsubscript{1}, sequential boost planned on CT\textsubscript{5}, 2) SIB: simultaneous integrated boost planned on CT\textsubscript{1}, 3) SIB adaptive radiation therapy (SIB-ART): planned on CT\textsubscript{1} and re-planned on CT\textsubscript{3}. Irradiated volumes, mean lung (MLD) and maximum heart dose (HD\textsubscript{max}) were projected and compared on CT\textsubscript{5}.

\textit{Results:} On average 62\% seroma reduction during RT was observed. Volumes receiving \(\geq107\%\) of prescribed whole breast dose were significantly smaller with SIB-ART compared to SEQ and SIB. The undesired volume receiving \(\geq95\%\) of prescribed total dose was also significantly smaller with SIB-ART. For SEQ, SIB-ART and SIB respectively, small but significant differences were found in MLD (4.2 vs. 4.6 vs. 4.7Gy) and in HD\textsubscript{max} for patients with left-sided breast cancer (39.9 vs. 35.8 vs. 36.9Gy).

\textit{Conclusions:} This study demonstrates a dosimetric advantage for patients with seroma when simultaneous integrated boost is used with re-planning halfway through treatment.

Introduction

Radiotherapy (RT) following breast-conserving surgery (BCS) has been proven to be effective in improving local control and long-term survival [1]. Following whole breast irradiation (WBI), an additional boost to the tumor bed was found to further decrease local recurrence [2]. In case the boost target volume (TV\textsubscript{boost}) on the initial planning CT includes post-operative seroma, it is frequently assumed that it does not change significantly during RT. However, prior studies have demonstrated 36\% to 50\% seroma reduction prior to RT [3,4], and 22\% to 62\% during RT [5-9]. Due to seroma reduction, the volume of breast tissue not intended to receive boost RT will become excessive towards the end of treatment, with increasing risk of fibrosis and additional worsening of cosmetic outcome [10,11].

Though we now know that TV\textsubscript{boost} is dynamic during RT and the irradiated volume should be kept as small as possible to optimize cosmetic results, no investigation has addressed the dosimetric consequences of different planning techniques specifically for boost volumes including seroma. Boost irradiation can be planned and delivered separately from or integrated with WBI. Planning of boost irradiation after WBI has the advantage of obtaining a second CT scan specifically for boost planning prior to boost irradiation, thereby accounting for seroma reduction during WBI. A large seroma reduction is primarily to be expected in patients with a large initial seroma volume [8,9], suggesting that a sequential boost will minimize irradiation overdose in this patient group. On the other hand, simultaneous integrated boost [12,13], with or without re-planning halfway through RT, can provide the benefit of improved dose distribution and shorter overall treatment course [14, 15]. To ultimately decide upon an optimal technique for patients with seroma, we need to know which plan results in the smallest excess breast dose outside the boost planning target volume (PTV\textsubscript{boost}).
In this study, we compared three different boost treatment planning techniques for patients who developed seroma after BCS: a sequential boost (SEQ) based on a sequential CT scan obtained in the fifth week of RT, simultaneous integrated boost (SIB) without adaptations, and SIB adaptive radiation therapy (SIB-ART) with adaptation based on a CT scan obtained in the third week of RT. The objective was to determine whether a tighter dose distribution at the start of treatment (SIB) outweighs the dosimetric advantage of planning the boost after WBI (SEQ) for patients with seroma. Furthermore, the merit of boost re-planning during treatment (SIB-ART) was evaluated.

Materials and methods

Patient Data

Twenty-one patients who received breast-conserving therapy in 2008 and developed seroma in the excision cavity after undergoing microscopically complete tumor excision were consecutively selected for this study. The patients were recruited from two different RT departments within The Netherlands: The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam (n=12) and Catharina Hospital, Eindhoven (n=9). No patients in our study received neo-adjuvant chemotherapy. An overview of patient characteristics is given in Table 1.

Imaging Data

All patients underwent CT (24-slice Somatom-Sensation-Open, Siemens, Forchheim, Germany or 16-slice Big-Bore, Philips Healthcare, Eindhoven, The Netherlands) as part of the standard planning for RT. Patients were scanned in supine orientation using arm and knee supports with a lead wire placed around the breast as an aid in generating the breast contour. The initial planning CT scan (CT1) was acquired one week prior to RT. Two additional CT scans were acquired in the third (CT3) and fifth week (CT5) of RT. CT3 and CT5 were registered to CT1 using rigid registration (translations only) of bony anatomy.

Planning Target Volumes and Organs at Risk

Volumes were specifically defined and delineated for this study to avoid differences between contributing institutions. The lungs were delineated using an automatic contouring tool and visually verified. The heart was manually delineated. The total breast target volume (TVbreast) was generated based on the field borders of the radiation field. The volume was restricted to 7mm inside the field borders, 7mm towards the skin, 5mm towards the lung, and 10mm margin towards the heart. All patients were operated without closure of the excision cavity, therefore the post-operative seroma was defined to be the “tumor bed”. The tumor bed was delineated by a trained radiation therapist using Pinnacle 8.1v (research version, Philips Radiation Oncology Systems, Milpitas, CA). All delineations were checked and approved by a radiation oncologist. To obtain the boost clinical target volume (CTVboost), the tumor bed was expanded by 10mm, subsequently ribs and muscles were excluded. Finally, a PTVboost suitable for inverse optimization was obtained by an additional 5mm expansion followed by a correction to exclude air and skin (plus 7mm margin).

Boost Delivery Techniques

For each patient, three photon beams treatment plans were generated with Pinnacle 8.1v using three different planning techniques: SEQ, SIB, and SIB-ART. The linear quadratic cell survival model was used to calculate fraction sizes and total doses in SIB and SIB-ART planning [17]. The resulting SIB and SIB-ART plans were biologically equivalent to the SEQ plans in the total dose delivered to the target volumes in 2Gy fractions assuming an α/β-ratio of 10Gy for the tumor bed (BED10).

SEQ
1. WBI 50.00Gy (25x2.00Gy) planned on CT1,
2. Subsequently boost of 16.00Gy (8x2.00Gy) planned on CT5.

SIB
Total boost RT of 64.40Gy in 28 fractions including:
- WBI 50.68Gy (28x1.81Gy) planned on CT1,
- Boost 13.72Gy (28x0.49Gy) also planned on CT1.

1 We didn’t consider evaluation of electron beams for delivery of the boost dose since photon beams are preferred over electron beams especially for deep-seated targets as investigated in this study [16].
After 15 fractions a new treatment plan is made based on CT3 to take part of the post-operative seroma reduction into account.

1. In the first 15 fractions boost RT of 34.50Gy includes:
   - WBI 27.15Gy (15x1.81Gy) planned on CT1,
   - Boost 7.35Gy (15x0.49Gy) planned on CT4.

2. In the final 13 fractions boost RT of 29.90Gy includes:
   - WBI 23.53Gy (13x1.81Gy) planned on CT3,
   - Boost 6.37Gy (13x0.49Gy) also planned on CT3.

In terms of total dose, the administered dose in SIB-ART is the same as SIB.

**Beam Setup and Plan Optimization**

**WBI.** For all three techniques WBI treatment planning consisted of simultaneous inverse optimization of two tangential glancing rectangular fields (medial and lateral) combined with two tangential IMRT fields with identical gantry angles. The rectangular fields were positioned according to the lead wire marking the outer breast contour. In the direction of the skin a 2cm margin was used to create glancing rectangular fields to take into account displacement of the breast due to breathing. Based on digitally reconstructed radiographs, Pinnacle skinviews (projection of the fields on the skin) and the CT data multileaf collimator shielding was used to protect the heart as much as possible. Optimization was limited to a maximum of eight segments ($\geq 9 \text{ cm}^2$) for the IMRT fields. A minimum of four monitor units were used per segment. A minimum of 80% of the whole breast dose was given with the two open fields.

**Boost irradiation.** One orthogonal and one or two tangential fields (depending on tumor location) were used for the boost.

For SEQ, boost fields are IMRT fields and the boost plan was created without taking into account the WBI plan. If the boundary of the PTV was 7mm from the skin, the multi-leaf collimator segments were positioned around the PTV. If the PTV extended to within 7mm from the skin, all leaves positioned within 7mm to the skin surface were opened in the skin direction.

For both SIB and SIB-ART, boost fields are conformal and set around the PTVboost with a margin of 6mm. Dose to boost and breast target volumes were simultaneously optimized.

**Treatment planning.** The setup of the tangential beams was chosen such as to achieve minimal irradiation of the contralateral breast. All plans were inversely optimized with the goal to achieve sufficient coverage of the target volumes and to minimize dose to heart and lungs. Furthermore, in order to minimize the volume with excess dose outside PTVboost, the dose to the whole breast minus PTVboost+6mm margin was minimized subject to the constraint that the dose to the whole breast doesn’t drop below the minimal required dose. For all three techniques, at least 97% of TVbreast and 99% of PTVboost should receive at least 95% of the prescribed dose. For all patients, plan optimization was started using a standard set of objectives. Subsequently, patient-specific tuning of the plans was performed without resetting the segments found in the initial optimization to further minimize dose to the heart and lungs.

**Analysis of coverage, dose distribution and normal tissues**

To establish ‘treatment’ doses (as opposed to ‘planned’ doses), for all dose distributions, a dose volume histogram (DVH) was calculated for the volume defined by the external contour of the patient, CTVboost and PTVboost as defined on CT3. Target coverage was determined by evaluating the relative volumes of both CTVboost and PTVboost receiving 95% of the prescribed dose.

For the whole patient (including PTVboost), the volume that received $\geq 107\%$ of the prescribed dose to the whole breast ($V_{\text{patient, } 107\%\text{ (breast-dose)}}$) was determined. Also the volume that received $\geq 95\%$ of the prescribed total dose ($V_{\text{patient, } 95\%\text{ (total-dose)}}$) was determined. Furthermore, the undesired volume (outside PTVboost) that received $\geq 95\%$ of the total dose ($V_{\text{outside PTV boost, } 95\%\text{ (total-dose)}}$) [14,18] was determined. In addition, maximum physical dose to the absolute heart volume (HDmax) and mean physical lung dose (MLD) were investigated.

**Statistical Analysis**

Since the data showed deviations from normal distributions, nonparametric statistical analyses were performed. On each of the variables obtained from the dose distributions a Friedman test was performed to establish differences between planning techniques. All significant effects were investigated post-hoc using Wilcoxon-signed-ranks tests. The significance of seroma reduction over time was determined by one-
sample t test. Furthermore, for each pair of treatment plans, we determined the correlations between the difference in $V_{\text{outside PTVboost}}$, 95%(total-dose) on the one hand and seroma volume as well as seroma volume reduction on the other hand. Correlations were computed as the Spearman ranked correlation. Statistical significance was assumed at $p \leq 0.05$.

**Results**

All generated treatment plans adhered to clinical requirements. An overview of the target coverage is given in Table 2. Table 3 summarizes the means and significant effects found for $V_{\text{patient}}$, 107%(breast-dose) > $V_{\text{patient}}$, 95%(total-dose) > $HD_{\text{max}}$ and MLD.

**Coverage and Dose Distribution**

All three techniques provide similar CTV$_{\text{boost}}$ coverage. SIB and SIB-ART perform slightly worse compared to SEQ concerning PTV$_{\text{boost}}$ coverage.

Figure 1 illustrates the total dose distribution ($V_{\text{patient}}$, 107%(breast-dose), $V_{\text{patient}}$, 95%(total-dose)) on CT$_3$ together with the tumor bed and PTV$_{\text{boost}}$ for the three different techniques for one patient. $V_{\text{patient}}$, 107%(breast-dose) was smallest for SIB-ART, followed by SIB and then SEQ ($p < 0.001$). $V_{\text{patient}}$, 107%(breast-dose) was on average reduced by 16% and 9% with SIB-ART when compared to SEQ and SIB, respectively, and a 7% reduction was demonstrated with SIB compared to SEQ.

The difference in $V_{\text{patient}}$, 95%(total-dose) was on average reduced by 13% and 19% ($p < 0.001$) with SIB-ART when compared to SEQ and SIB, respectively. Also a statistically significant difference in $V_{\text{patient}}$, 95%(total-dose) was found between SEQ and SIB ($p = 0.003$) with an average increase of 8% with SIB.

**Normal Tissues**

The difference in physical $HD_{\text{max}}$ for patients with left-sided breast cancer (n=11) was statistically significant between the three techniques ($p \leq 0.04$). SIB-ART demonstrated the smallest mean volume, followed by SIB and then SEQ. For patients with right-sided breast cancer (n=10), the smallest mean $HD_{\text{max}}$ was found with SEQ. The difference in physical $HD_{\text{max}}$ was statistically significant when comparing SEQ to both SIB and SIB-ART ($p = 0.03$ and $p = 0.01$ respectively). No significant difference was found between SIB and SIB-ART.

The difference in physical MLD between the three techniques was small but statistically significant ($p \leq 0.02$). The smallest mean MLD was found with SEQ followed by SIB-ART and SIB.

The difference in $V_{\text{outside PTVboost}}$, 95%(total-dose) was found to be statistically significant for SIB-ART compared to both SEQ and SIB ($p < 0.001$). On average a reduction of 35% and 26% was observed with SIB-ART when compared to SIB and SEQ, respectively.

**Seroma Volume, Seroma Reduction and Excess Dose**

The mean seroma volumes for CT$_1$, CT$_3$ and CT$_5$ were 63cm$^3$ (range: 18–218cm$^3$), 32cm$^3$ (range: 8–122cm$^3$) and 25cm$^3$ (range: 6–102cm$^3$), respectively. Significant total seroma reduction during RT was demonstrated (mean = 62%, range: 38–85%, $p < 0.001$, one-sample t-test). Larger seroma reduction (77% of the total reduction) was observed between CT$_1$ and CT$_3$ than between CT$_3$ and CT$_5$ ($p = 0.001$, Wilcoxon-signed-ranks test).

The absolute difference in $V_{\text{outside PTVboost}}$, 95%(total-dose) between SIB and SIB-ART was found to be statistically significantly correlated with both seroma volume on CT$_1$ ($p = 0.002$, $r_s = 0.6$) and absolute seroma reduction between CT$_1$ and CT$_3$ ($p = 0.001$, $r_s = 0.7$) (Fig. 2). This indicates that patients with a larger initial seroma volume or a larger seroma reduction between CT$_1$ and CT$_3$ benefit more from SIB-ART compared to SIB.

**Discussion**

The aim of this study was to retrospectively compare three boost RT planning techniques (SEQ, SIB and SIB-ART) in patients who developed seroma after breast-conserving surgery. This study showed that irradiated boost volumes were significantly smaller with SIB-ART, despite the apparent advantage of a sequential boost with respect to seroma shrinkage. The three techniques only slightly differed in dose delivery to the lungs and heart. Therefore, our study indicates a clinical preference for SIB-ART in post-operative breast cancer patients with seroma.
Comparing SEQ, SIB and SIB-ART

Although SEQ, SIB and SIB-ART were planned according to their clinical protocol, performance evaluation was done on a CT scan acquired in the fifth week of RT (CT5). This ensured a clinical comparison, rather than a planning comparison, accounting for and comparing the techniques including the features inherent to SEQ and SIB(-ART). On the one hand, since boost planning for SEQ is actually performed on CT3, and our patients demonstrate significant seroma reduction during RT, this provided an advantage for SEQ planning when compared to SIB(-ART). On the other hand, the combination of the slightly lower physical dose (to obtain biologically equivalent plans) with inherently tighter total planned dose distributions [14,18] provided an advantage for SIB(-ART). In this study, these features were deliberately maintained to provide a fair clinical comparison.

Coverage and Dose Distribution

We found that overall irradiated volumes (whole breast as well as boost) were always significantly smaller with SIB-ART compared to both SIB and SEQ. Nevertheless, boost target coverage was slightly worse for both SIB and SIB-ART compared to SEQ. This is due to geometrical changes in breast tissue that occurred in three patients during the third and fifth week of RT. Therefore, boost target volumes assessed for SIB and SIB-ART in CT scans obtained pre-treatment and in the third week of RT were no longer representative of the boost volumes in the fifth week of RT for these patients. This finding indicates the importance of monitoring the excision cavity for changes during RT in order to re-define target volume and modify treatment plans when needed [19].

Normal Tissues

For patients with right-sided breast cancer, HDmax was found to be significantly lower for SEQ when compared to both SIB and SIB-ART. Nevertheless, since RT for patients with right-sided breast cancer generally involves smaller cardiac dose delivery, HDmax was for all three techniques smaller than 8Gy on average. It is therefore to be questioned whether the small differences in dosage have any clinical impact [20].

For all three techniques, the average mean physical lung dose was well below the maximum normalized total lung dose (7.5Gy) that could result in less than 1% risk of radiation pneumonitis Grade 2 or higher [21].

Since boost treatment planning for SEQ is planned on a CT scan obtained in the fifth week of RT, one might expect superiority of the performance of SEQ when evaluating Voutside PTVboost, 95%(total-dose) in the fifth week of RT. Conversely, evaluation of the performance of the three techniques in this study showed a reduction of 26% in Voutside PTVboost, 95%(total-dose), when using SIB-ART compared to SEQ. On the other hand, an increase of 16% in Voutside PTVboost, 95%(total-dose) was observed when using SIB compared to SEQ. Note that the performances of SIB and SIB-ART are biased to their disadvantage as a consequence of the evaluation of the total plan on CT5. Nevertheless, the current results indicate a preference for SIB-ART with respect to minimizing Voutside PTVboost, 95%(total-dose).

Clinical Implications

Our study showed that for patients who demonstrated seroma reduction, a SIB-ART planning technique is clinically preferable to a SEQ planning technique as the combined effect of a tighter dose distribution and re-planning midway through RT is most successful in achieving excess dose reduction. The clinical implication would be replacing SEQ with SIB(-ART). Nevertheless, a difficult issue remains: what specific dosimetric gain is clinically relevant enough to spend the additional time associated with re-planning? For each 100cm² increase in irradiated boost volume a fourfold increase in risk of fibrosis was observed [10]. Therefore, a reduction of 50cm² in volume of excess dose during RT can be considered clinically significant and should be taken into consideration. The graphs in Figure 2 could be used to derive clinical indications for the decision to start monitoring and to create the adaptive plan. Two thresholds can be derived: 1) patients with an initial seroma volume ≥40cm³ should be monitored and 2) patients with seroma reduction of ≥20cm³ in the first four weeks after acquisition of the initial planning CT should be re-planned. In our investigated patient group 48% of the patients would benefit (reduction of ≥50cm³ in volume of excess dose) from SIB-ART compared to SIB. However, whether these thresholds are effective should be addressed in a larger patient group in future investigations.

Variation in boost target volume delineation in breast RT is a well known issue [22-24]. However, it has been shown that changes in boost volume during RT due to seroma shrinkage are significant in relation to
clinical interobserver variations [25]. Furthermore, delineation variation is smaller when seroma is present [22,24]. In case SIB-ART is used in clinical practice it is advisable to have all delineation for a specific patient done by the same physician. This way delineation variation is minimized and undesirable adaptation of the location of the boost target volume is prevented.

**Limitations**

It is to be questioned whether SIB-ART would be preferable to SIB in a subselection of patients that demonstrates minor seroma reduction in the first three weeks of RT. This was not investigated in our current study and should be addressed in future investigations.

The clinical fractionation schedule for SIB was calculated using an α/β-ratio of 10Gy. However, recent data suggest lower α/β-ratio (e.g. 3.6Gy) could be more applicable [26,27]. Nevertheless, our study represents the current clinical practice in terms of breast RT dosing.

**Conclusions**

Seroma is frequently seen in patients after breast-conserving surgery. Reduction is normally seen during the first weeks of adjuvant radiotherapy [3,9]. Our study demonstrates that, for patients with seroma reduction, a tighter dose distribution from the start of treatment (SIB) outweighs the advantage of sequential boost planning (SEQ) provided that the delivery of SIB is re-planned halfway through treatment. This leads us to the conclusion that SIB-ART is the optimal boost radiation treatment planning technique and should be considered for standard clinical practice.

**Conflict of interest statement**

The authors of this manuscript have no actual or potential conflicts of interest to disclose.

**Acknowledgments**

The authors would like to thank J. van der Leer, RT(T) (Department of Radiation Therapy, Catharina Hospital, Eindhoven, The Netherlands) and D. Minkema, RT(T) (Department of Radiation Oncology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands) for their contributions to this study. Financial support of this work was provided by the Dutch Cancer Society (Grant No. KWF 2008-4024).

**References**

Figure 1 An illustration of the total dose distribution on the CT scan acquired in the fifth week of RT. Both the volume that received $\geq 107\%$ of the prescribed dose to the whole breast (light grey line) and the volume that received $\geq 95\%$ of the prescribed total dose (dark grey line) are illustrated. Also the tumor bed (white overlay) and boost planning target volume (black overlay) used for planning are visualized. The tumor bed and boost planning target volume visualized are derived from the initial planning CT scan acquired before RT, CT scan acquired in the third and fifth week of RT for SIB, SIB-ART and SEQ respectively.
Figure 2 Left: Seroma volume derived from the initial planning CT scan (CT\textsubscript{1}) versus the difference between SIB and SIB-ART in undesired volume receiving $\geq 95\%$ of the total dose ($V_{\text{outside PTVboost, 95\%(total-dose)}}$) evaluated in the fifth week of RT. Right: Seroma reduction between CT\textsubscript{1} and the CT scan acquired in the third week of RT (CT\textsubscript{3}) versus the difference in $V_{\text{outside PTVboost, 95\%(total-dose)}}$ evaluated in the fifth week of RT.
### Tables

#### Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>SEQ</th>
<th>SIB</th>
<th>SIB-ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y) at initiation of radiation therapy</td>
<td></td>
<td>Mean (Range)</td>
<td>59 (38–81)</td>
</tr>
<tr>
<td>T stage (n)</td>
<td></td>
<td>Tis</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T1</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T2</td>
<td>4</td>
</tr>
<tr>
<td>N stage (n)</td>
<td></td>
<td>N0</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N3</td>
<td>1</td>
</tr>
<tr>
<td>M stage (n)</td>
<td></td>
<td>M0</td>
<td>21</td>
</tr>
<tr>
<td>Time between surgery and CT₁ (days)</td>
<td></td>
<td>Mean (Range)</td>
<td>27 (15–48)</td>
</tr>
<tr>
<td>Time between surgery and CT₃ (days)</td>
<td></td>
<td>Mean (Range)</td>
<td>51 (35–75)</td>
</tr>
<tr>
<td>Time between surgery and CT₅ (days)</td>
<td></td>
<td>Mean (Range)</td>
<td>68 (52–89)</td>
</tr>
<tr>
<td>Actual radiation treatment (n)</td>
<td></td>
<td>SEQ</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SIB</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SIB-ART</td>
<td>6</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- CT₁: initial planning CT acquired before start RT.
- CT₃: CT scan acquired in the third week of RT.
- CT₅: CT scan acquired in the fifth week of RT.

#### Table 2. Target coverage (relative volumes receiving 95% of the prescribed dose) results are presented as mean values with ranges in parentheses. The coverage for PTV<sub>boost</sub> and CTV<sub>boost</sub> defined on the CT scan acquired in the fifth week of RT are given.

<table>
<thead>
<tr>
<th>Variable</th>
<th>SEQ</th>
<th>SIB</th>
<th>SIB-ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTV&lt;sub&gt;boost&lt;/sub&gt;</td>
<td>100.0 (99.6–100.0)</td>
<td>98.7 (91.7–100.0)</td>
<td>97.6 (83.0–100.0)</td>
</tr>
<tr>
<td>CTV&lt;sub&gt;boost&lt;/sub&gt;</td>
<td>99.7 (98.0–100.0)&lt;sup&gt;*&lt;/sup&gt;</td>
<td>99.8 (99.0–100.0)</td>
<td>99.6 (94.8–100.0)</td>
</tr>
</tbody>
</table>

*Under-dosage within CTV<sub>boost</sub> (e.g. tumor bed near the skin) has a larger effect on CTV<sub>boost</sub> coverage than on PTV<sub>boost</sub> coverage when expressing the coverage as a percentage of the volume.
Table 3. Means of all investigated variables for the three different planning techniques, \( p \)-values of Friedman tests are reported as well as an indication of the specific effect as found by Wilcoxon-signed-ranks tests. For example, SIB-ART<SIB<SEQ means that all differences are significant. SEQ~SIB~SIB-ART means that none of the differences are significant.

<table>
<thead>
<tr>
<th>Variable</th>
<th>mean</th>
<th>Friedman</th>
<th>Wilcoxon</th>
</tr>
</thead>
<tbody>
<tr>
<td>( V_{\text{patient, 107% (breast-dose)}} ) (cm(^3))</td>
<td>584.5</td>
<td>536.8</td>
<td>485.5</td>
</tr>
<tr>
<td>( V_{\text{patient, 95% (total-dose)}} ) (cm(^3))</td>
<td>273.6</td>
<td>289.4</td>
<td>234.2</td>
</tr>
<tr>
<td>( V_{\text{outside PTV boost, 95% (total-dose)}} ) (cm(^3))</td>
<td>134.4</td>
<td>150.1</td>
<td>95.0</td>
</tr>
<tr>
<td>HD(_{\text{max}}) * (Gy)</td>
<td>Left</td>
<td>39.9</td>
<td>36.9</td>
</tr>
<tr>
<td></td>
<td>Right</td>
<td>5.7</td>
<td>7.4</td>
</tr>
<tr>
<td>MLD* (Gy)</td>
<td>4.2</td>
<td>4.6</td>
<td>4.5</td>
</tr>
</tbody>
</table>

**Abbreviations:**

\( V_{\text{patient, 107\% (breast-dose)}} \): volume of the patient that received ≥107\% of the prescribed dose to the whole breast.

\( V_{\text{patient, 95\% (total-dose)}} \): volume of the patient that received ≥95\% of the prescribed total dose.

\( V_{\text{outside PTV boost, 95\% (total-dose)}} \): undesired volume receiving ≥95\% of the total dose.

HD\(_{\text{max}}\): maximum physical dose to the absolute heart volume.

MLD: mean physical lung dose.

*: Derived from dose distributions that are uncorrected for fractionation effects.

Left: left-sided breast cancer.

Right: right-sided breast cancer.